DEA Reschedules Hydrocodone Combination Products

Posted in Latest News on September 9, 2014.

On Friday, August 22nd, the U. S. Drug Enforcement Administration (DEA) published a Final Rule moving hydrocodone combination products (HCPs) from Schedule III to the more-restrictive Schedule II. This Final Rule imposes the regulatory controls and sanctions applicable to Schedule II substances on those who handle or propose to handle HCPs. The rule goes into effect 45 days from its publish date.



More Latest News

Important notice regarding Rhopressa
February 12, 2019

The board approved Rhopressa (netarsudil ophthalmic solution) 0.02% for addition to Rule 64B13-18.002. Effective January 25, 2019, Licensees are now permitted to prescribe Rhopressa. Continue reading


Florida Jurisprudence CE Requirement
February 11, 2019

The Board of Optometry voted to waive the 2-hour Florida Jurisprudence requirement for all out-of-state licensees for the current biennium only. Click Here for more information. Continue reading